Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
bortezomib
hexosamine biosynthetic pathway
metabolism
multiple myeloma
oxidative stress
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
30 04 2020
30 04 2020
Historique:
received:
07
03
2020
revised:
31
03
2020
accepted:
28
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
7
4
2021
Statut:
epublish
Résumé
The proteasome inhibitor bortezomib (BTZ) has emerged as an effective drug for the treatment of multiple myeloma even though many patients relapse from BTZ therapy. The present study investigated the metabolic pathways underlying the acquisition of bortezomib resistance in multiple myeloma. We used two different clones of multiple myeloma cell lines exhibiting different sensitivities to BTZ (U266 and U266-R) and compared them in terms of metabolic profile, mitochondrial fitness and redox balance homeostasis capacity. Our results showed that the BTZ-resistant clone (U266-R) presented increased glycosylated UDP-derivatives when compared to BTZ-sensitive cells (U266), thus also suggesting higher activities of the hexosamine biosynthetic pathway (HBP), regulating not only protein
Identifiants
pubmed: 32365811
pii: biom10050696
doi: 10.3390/biom10050696
pmc: PMC7277183
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Hexosamines
0
Bortezomib
69G8BD63PP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : AIRC (FDR)
ID : AIRC IG2018-ID22131
Pays : International
Références
Clin Biochem. 2005 Nov;38(11):997-1008
pubmed: 16139832
Cancer Treat Rev. 2018 Nov;70:199-208
pubmed: 30245231
Trends Cell Biol. 2019 Jul;29(7):580-590
pubmed: 30929794
Nat Metab. 2019 Sep;1(9):861-867
pubmed: 31598584
Transl Stroke Res. 2013 Dec;4(6):618-34
pubmed: 24323416
Mol Cell Biol. 2019 Dec 11;40(1):
pubmed: 31636161
BMC Biol. 2019 Jul 4;17(1):52
pubmed: 31272438
Arch Biochem Biophys. 1984 Sep;233(2):573-81
pubmed: 6486800
Free Radic Res. 2018 Jun;52(6):648-660
pubmed: 29620489
PLoS One. 2010 Jul 22;5(7):e11707
pubmed: 20661474
Curr Top Med Chem. 2018;18(30):2584-2598
pubmed: 30499398
PLoS One. 2013 Dec 26;8(12):e83719
pubmed: 24386263
Toxicol Appl Pharmacol. 2018 Nov 15;359:24-33
pubmed: 30236989
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 15;851(1-2):257-67
pubmed: 17324645
Glycobiology. 2014 Apr;24(4):392-8
pubmed: 24474243
EBioMedicine. 2019 Jan;39:612-620
pubmed: 30545798
Int J Mol Med. 2017 May;39(5):1127-1136
pubmed: 28339017
Oncotarget. 2016 May 17;7(20):28868-80
pubmed: 26930712
Cells. 2019 Mar 27;8(4):
pubmed: 30934711
Int J Cell Biol. 2010;2010:170215
pubmed: 20169117
Toxicology. 2011 Feb 4;280(1-2):24-32
pubmed: 21108985
Cell. 2016 Jul 28;166(3):555-566
pubmed: 27471965
Blood. 2013 Aug 15;122(7):1243-55
pubmed: 23823317
J Biomed Res. 2012 Jul;26(4):268-73
pubmed: 23554759
Mitochondrion. 2012 Jan;12(1):5-13
pubmed: 21406254
Cell Death Dis. 2018 Mar 7;9(3):377
pubmed: 29515119
Cell Rep. 2018 Mar 13;22(11):2827-2836
pubmed: 29539413
Trends Cell Biol. 2008 Apr;18(4):165-73
pubmed: 18296052
Exp Mol Med. 2017 Aug 11;49(8):e365
pubmed: 28798402
Front Genet. 2019 May 14;10:435
pubmed: 31139208
Front Endocrinol (Lausanne). 2018 Sep 06;9:522
pubmed: 30237786
Expert Rev Proteomics. 2018 Dec;15(12):1033-1052
pubmed: 30427223
Cardiovasc Res. 2008 Jul 15;79(2):208-17
pubmed: 18430751
Anticancer Res. 2013 Aug;33(8):3047-52
pubmed: 23898059
Oncotarget. 2017 May 30;8(22):35863-35876
pubmed: 28415782
Neuropharmacology. 2019 Dec 1;160:107755
pubmed: 31487495
Essays Biochem. 2018 Jul 20;62(3):341-360
pubmed: 30030364
Cancers (Basel). 2019 Apr 19;11(4):
pubmed: 31010244
Cell Death Dis. 2018 Apr 30;9(5):485
pubmed: 29706631
Biochem Biophys Res Commun. 2013 Feb 22;431(4):693-7
pubmed: 23375814
Leukemia. 2012 Apr;26(4):757-68
pubmed: 21941364
FEBS J. 2014 Aug;281(16):3591-608
pubmed: 24938479
Blood. 2006 Jun 15;107(12):4907-16
pubmed: 16507771
Mol Cancer Ther. 2008 Aug;7(8):2298-307
pubmed: 18723477
J Clin Invest. 2018 Nov 1;128(11):4924-4937
pubmed: 30130254
J Hematol Oncol. 2016 Sep 06;9(1):82
pubmed: 27599459
Curr Top Microbiol Immunol. 2002;268:43-72
pubmed: 12083008
Mol Neurobiol. 2019 Nov;56(11):7338-7354
pubmed: 31030416
Anal Biochem. 2003 Nov 1;322(1):51-9
pubmed: 14705780
Mol Med Rep. 2016 Feb;13(2):1774-80
pubmed: 26719045
Blood. 2019 Jan 10;133(2):156-167
pubmed: 30455381
Cancer Metab. 2017 Aug 29;5:7
pubmed: 28855983
Proteomics. 2009 Dec;9(24):5398-9
pubmed: 19902428
Cancer Res. 2015 May 15;75(10):2071-82
pubmed: 25769724
Nat Commun. 2017 Jul 25;8(1):120
pubmed: 28743912
Blood. 2004 Oct 15;104(8):2458-66
pubmed: 15217830
Leukemia. 2009 Jun;23(6):1098-105
pubmed: 19225532
Int J Mol Sci. 2019 Mar 26;20(6):
pubmed: 30917493
Leukemia. 2019 Apr;33(4):863-883
pubmed: 30683909
Traffic. 2014 Apr;15(4):347-61
pubmed: 24423194
J Biol Chem. 2017 Mar 17;292(11):4499-4518
pubmed: 28100784
Leukemia. 2016 Nov;30(11):2198-2207
pubmed: 27118406
Cancer Res. 2005 May 1;65(9):3828-36
pubmed: 15867381
Mol Cancer Ther. 2018 Oct;17(10):2226-2237
pubmed: 30082471
J Comp Neurol. 2020 Feb 1;528(2):231-243
pubmed: 31364764
Cell Death Dis. 2018 Apr 25;9(5):488
pubmed: 29695796